Sep 30, 2025
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented
Sep 22, 2025
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented
Sep 18, 2025
IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes
Aug 13, 2025
IceCure Reports Financial & Operational Results for the First Half of 2025
Jul 29, 2025
IceCure Announces Expiration and Results of Approximately Two Times Over-Subscribed Rights Offering for Aggregate Gross Proceeds of $10.0 Million
Jul 25, 2025
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
Jul 24, 2025
IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period
Jul 03, 2025
IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025
Jun 25, 2025
IceCure Announces Record Date for Rights Offering for Up to $10 Million
May 28, 2025
IceCure Medical Reports First Quarter 2025 Financial Results
May 21, 2025
IceCure to Report First Quarter 2025 Financial & Operational Results on May 28, 2025
Apr 30, 2025
IceCure Announces Positive FDA Development: Understanding on Path Forward for Marketing Authorization of ProSense® Cryoablation in Women 70+ with Early-Stage Breast Cancer
Apr 28, 2025
IceCure Exhibits ProSense® & Sponsors Breast Cryoablation Courses at the Society of Breast Imaging Symposium
Mar 27, 2025
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America
Mar 24, 2025
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate
Mar 21, 2025
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025
Mar 20, 2025
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer
Mar 17, 2025
IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology
Mar 10, 2025
Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery
Feb 24, 2025
IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense(TM) Cryoablation System in Israel